<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500329</url>
  </required_header>
  <id_info>
    <org_study_id>BRMH 26-2014-124</org_study_id>
    <nct_id>NCT02500329</nct_id>
  </id_info>
  <brief_title>Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients</brief_title>
  <official_title>Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients (GetUp Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      This is a phase 4, single center, randomized, open-labeled study. The primary objective of
      the study is to compare effect of gemigliptin and acarbose on endothelial function.

      Subjects are randomized to gemigliptin or acarbose group and maintained intial treatment for
      4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial function (reactive hyperemic index)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial 2hour glucose</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated albumin</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Endothelial Function</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Gemigliptin</condition>
  <condition>Acarbose</condition>
  <arm_group>
    <arm_group_label>gemigliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gemigliptin for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acarbose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>acarbose for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin</intervention_name>
    <description>Gemigliptin for 4 weeks</description>
    <arm_group_label>gemigliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <description>Acarbose for 4 weeks</description>
    <arm_group_label>acarbose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age: 20-80yrs

          -  patients with type 2 diabetes (duration of diabetes &gt;=3 months)

          -  HbA1c :&gt;7.0 and &lt;=9.0% on metformin monotherapy

          -  no changes on medications during recent 3 months.

        Exclusion Criteria:

          -  patients with type 1 diabetes

          -  history of medications including Î±-glucosidase inhibitor, glinide, GLP-1 analogue,
             other DPP-4 Inhibitors, or insulin during recent 3 months.

          -  history of acute diabetic complication, acute coronary events, or coronary bypass
             surgery/interventions during recent 6 months.

          -  patients with congestive heart failure (NYHA II~IV) or clinically significant
             ventricular arrhythmia

          -  serum ALT or AST&gt; 2.5 x upper normal range

          -  serum direct bilirubin &gt; 1.3 x upper normal range

          -  serum creatinine &gt; (men) 1.5 mg/dL, (women)&gt;1.4 mg/dL

          -  smoker

          -  pregnant women, or breast-feeding women

          -  medication with acetylsalicylic acid or vitamin K antagonist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Kyong Moon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boramae medical center, 20 Boramae-ro 5-gil,Dongjak-Gu,Seoul 156-707, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Kyong Moon</last_name>
    <phone>+82-2-870-2226</phone>
    <email>mkmoon@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bo Kyung Koo</last_name>
    <phone>+82-2-870-2225</phone>
    <email>bokyungkoomd@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boramae medical center</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bokyung Koo</last_name>
      <email>bokyungkoomd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Min Kyong Moon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>July 14, 2015</last_update_submitted>
  <last_update_submitted_qc>July 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Min Kyong Moon</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

